Chronic kidney disease and the skeleton

Abstract

Fractures across the stages of chronic kidney disease (CKD) could be due to osteoporosis, some form of renal osteodystrophy defined by specific quantitative histomorphometry or chronic kidney disease–mineral and bone disorder (CKD–MBD). CKD–MBD is a systemic disease that links disorders of mineral and bone metabolism due to CKD to either one or all of the following: abnormalities of calcium, phosphorus, parathyroid hormone or vitamin D metabolism; abnormalities in bone turnover, mineralization, volume, linear growth or strength; or vascular or other soft-tissue calcification. Osteoporosis, as defined by the National Institutes of Health, may coexist with renal osteodystrophy or CKD–MBD. Differentiation among these disorders is required to manage correctly the correct disorder to reduce the risk of fractures. While the World Health Organization (WHO) bone mineral density (BMD) criteria for osteoporosis can be used in patients with stages 1–3 CKD, the disorders of bone turnover become so aberrant by stages 4 and 5 CKD that neither the WHO criteria nor the occurrence of a fragility fracture can be used for the diagnosis of osteoporosis. The diagnosis of osteoporosis in stages 4 and 5 CKD is one of the exclusion—excluding either renal osteodystrophy or CKD–MBD as the cause of low BMD or fragility fractures. Differentiations among the disorders of renal osteodystrophy, CKD–MBD or osteoporosis are dependent on the measurement of specific biochemical markers, including serum parathyroid hormone (PTH) and/or quantitative bone histomorphometry. Management of fractures in stages 1–3 CKD does not differ in persons with or without CKD with osteoporosis assuming that there is no evidence for CKD–MBD, clinically suspected by elevated PTH, hyperphosphatemia or fibroblast growth factor 23 due to CKD. Treatment of fractures in persons with osteoporosis and stages 4 and 5 CKD is not evidence-based, with the exception of post-hoc analysis suggesting efficacy and safety of specific osteoporosis therapies (alendronate, risedronate and denosumab) in stage 4 CKD. This review also discusses how to diagnose and manage fragility fractures across the five stages of CKD.

Fractures: due to osteoporosis or kidney disease?

Distinguishing between fractures related to kidney disease or osteoporosis is clinically challenging but important for treatment. Paul Miller from the Colorado Center for Bone Research in Lakewood, USA, reviewed the intimate biological relationships between the kidney and skeleton that can result in bone diseases that increase the risk of low-trauma fracture. Diagnosing whether fractures are related to chronic kidney disease (CKD) or osteoporosis is important as patients are managed differently. Diagnosis can be difficult because both diseases are characterized by low bone mineral density and low-trauma fractures. Analyzing bone structure and biomarkers of bone turnover should exclude osteoporosis in patients with severe CKD and low-trauma fractures. Although more information is needed on the use of approved osteoporosis drugs in CKD-related bone disease, drugs in development may offer more targeted therapy.

References

[1] Miller PD. Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis, 2014, 64: 290-304

[2] Miller PD. Chronic kidney disease and osteoporosis: evaluation and management. Bonekey Rep, 2014, 3: 542

[3] Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult U.S. population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis, 2013, 41: 1-12

[4] Levey AS, Coresh J, Balk E et al National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med, 2003, 139: 137-147

[5] Levey AS, Eckardt KU, Tsukamoto Y et al Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int, 2005, 67: 2089-2100

[6] Stevens LA, Levey AS. Chronic kidney disease in the elderly—how to assess risk. N Engl J Med, 2005, 352: 2122-2124

[7] Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med, 2006, 354: 2473-2483

[8] National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcomes Quality Initiative. Am J Kidney Dis, 2002, 39: S1-S266

[9] Kirsztajn GM, Suassuna JH, Bastos MG. Dividing stage 3 of chronic kidney disease (CKD): 3A and 3B. Kidney Int, 2009, 76: 462-463

[10] Jüppner H, Wolf M, Salusky IB. FGF-23: more than a regulator of renal phosphate handling? J Bone Miner Res, 2010, 25: 2091-2097

[11] Silver J, Naveh-Many T. FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol, 2013, 9: 641-649

[12] Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int Suppl 2009; (113): S1–S130.

[13] Coen G, Ballanti P, Bonucci E et al Bone markers in the diagnosis of low turnover osteodystrophy in hemodialysis patients. Nephrol Dial Transplant, 1998, 13: 2294-2302

[14] Couttenye MM, D’Haese PC, van Hoof VO et al Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in hemodialysis patients. Nephrol Dial Transplant, 1996, 11: 1065-1072

[15] Garrett G, Sardiwal S, Lamb EJ, Goldsmith DJ. PTH—a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol, 2013, 8: 299-312

[16] NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy Osteoporosis prevention, diagnosis, and therapy. JAMA, 2001, 285: 785-795

[17] Miller PD. Guidelines for the diagnosis of osteoporosis: T-scores vs fractures. Rev Endocr Metab Disord, 2006, 7: 75-89

[18] Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser, 1994, 843: 1-129

[19] Melton LJ 3rd How many women have osteoporosis now? J Bone Miner Res, 1995, 10: 175-177

[20] Baim S, Binkley N, Bilezikian JP et al Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom, 2008, 11: 75-91

[21] Bouxsein ML. Non-invasive measurements of bone strength: promise and peril. J Musculoskelet Neuronal Interact, 2004, 4: 404-405

[22] Seeman E. Bone quality: the material and structural basis of bone strength. J Bone Miner Metab, 2008, 26: 1-8

[23] Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int, 2008, 19: 385-397

[24] Engelke K, Adams JE, Armbrecht G et al Implementation and use of FRAX in clinical practice. J Clin Densitom, 2013, 14: 226-236

[25] Leslie WD, Lix LM. Comparison between various fracture risk assessment tools. Osteoporos Int, 2014, 25: 1-21

[26] Hans D, Goertzen AL, Krieg MA, Leslie WD. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res, 2011, 26: 2762-2769

[27] Keaveny TM. Biomechanical computed tomography-noninvasive bone strength analysis using clinical computed tomography scans. Ann NY Acad Sci, 2010, 1192: 57-65

[28] Krueger D, Fidler E, Libber J, Aubier-Rozier B, Hans D, Binkley N. Spine trabecular bone score subsequent to bone mineral density improves fracture discrimination in women. J Clin Densitom, 2014, 17: 60-65

[29] Silva BC, Leslie WD, Resch H et al Trabecular Bone Score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res, 2014, 29: 518-530

[30] Ensrud KE, Lui LY, Taylor BC et al Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med, 2007, 167: 133-139

[31] Dukas L, Schacht E, Stähelin HB. In elderly men and women treated for osteoporosis a low creatinine clearance of < 65 ml/min is a risk factor for falls and fractures. Osteoporos Int, 2005, 16: 1683-1690

[32] Fried LF, Biggs ML, Shlipak MG et al Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol, 2007, 18: 282-286

[33] Nickolas TL, Cremers S, Zhang A et al Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol, 2011, 22: 1560-1572

[34] Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int, 2008, 74: 721-731

[35] Alem AM, Sherrard DJ, Gillen DL et al Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int, 2000, 58: 396-399

[36] Ball AM, Gillen DL, Sherrard D et al Risk of hip fracture among dialysis and renal transplant recipients. JAMA, 2002, 288: 3014-3018

[37] Jadoul M, Albert JM, Akiba T et al Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int, 2006, 70: 1358-1366

[38] Stehman-Breen CO, Sherrard DJ, Alem AM et al Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int, 2000, 58: 2200-2205

[39] Ensrud KE. Fracture risk in CKD. Clin J Am Soc Nephrol, 2013, 8: 1282-1283

[40] Jamal SA, West SL, Miller PD. Bone and kidney disease: diagnostic and therapeutic implications. Curr Rheumatol Rep, 2012, 14: 217-223

[41] Miller PD. Unrecognized and underappreciated secondary causes of osteoporosis. Endocrinol Metab Clin North Am, 2012, 41: 613-628

[42] Jüppner H, Wolf M, Salusky IB. FGF-23: more than a regulator of renal phosphate handling? J Bone Miner Res, 2010, 25: 2091-2097

[43] Cejka D, Herberth J, Branscum AJ et al Sclerostin and Dikkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol, 2011, 6: 877-882

[44] Parfitt AM, Drezner MK, Glorieux FH et al Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res, 1987, 2: 595-610

[45] Dempster DW, Compston JE, Dreznar MK et al Standarized nomenclature, symbols, and units for bone histomorphonetry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res, 2013, 28: 2-17

[46] Andress DL, Sherrard DJ, Schrier RW. The osteodystrophy of chronic renal failure. Diseases of the kidney and urinary tract, 2003 Philadelphia, PA Lippincott Williams and Wilkins 2735-2768

[47] Miller PD. The role of bone biopsy in patients with chronic renal failure. Clin J Am Soc Nephrol, 2008, 3: S140-S150

[48] Frost HM. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res, 1969, 3: 211-237

[49] Hitt O, Jaworski ZF, Shimizu AG, Frost HM. Tissue-level bone formation rates in chronic renal failure, measured by means of tetracycline bone labeling. Can J Physiol Pharmacol, 1970, 48: 824-828

[50] Parfitt AM. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens, 2003, 12: 387-403

[51] Trueba D, Sawaya BP, Mawad H, Malluche HH. Bone biopsy: indications, techniques, and complications. Semin Dial, 2003, 16: 341-345

[52] Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res, 2013, 28: 2049-2059

[53] Gal-Moscovici A, Sprague SM. Osteoporosis and chronic kidney disease. Semin Dial, 2007, 20: 423-430

[54] Lamb EJ, Vickery S, Ellis AR. Parathyroid hormone, kidney disease, evidence and guidelines. Ann Clin Biochem, 2007, 44: 1-4

[55] Jamal SA, West SL, Miller PD. Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int, 2012, 23: 1191-1198

[56] Zangeneh F, Clarke BL, Hurley DL, Watts NB, Miller PD. Chronic kidney disease–mineral and bone disorder (CKD–MBDs): what the endocrinologist needs to know. Endocr Pract, 2014, 20: 500-516

[57] Fang Y, Ginsburg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA. Early chronic kidney disease–mineral bone disorder stimulates vascular calcification. Kidney Int, 2014, 85: 142-150

[58] Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis, 2007, 49: 674-681

[59] Jamal S, Cheung AM, West S, Lok C. Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporos Int, 2012, 23: 2805-2813

[60] West SL, Jamal SA. The interpretation and utility of bone mineral by dual energy X-ray absorptiometry in chronic kidney disease. Semin Dial, 2014, 27: 569-571

[61] Boyce BF. Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res, 2013, 28: 711-722

[62] Takyar FM, Tonna S, Ho PW et al Ephrin B2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. J Bone Miner Res, 2013, 28: 912-925

[63] Canalis E. Wnt signaling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol, 2013, 9: 575-583

[64] Rhee Y, Lee EY, Lezcano V et al Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes. J Biol Chem, 2013, 288: 29809-29820

[65] Boyce BF. Advances in the regulation of osteoblasts and osteoclasts functions. J Dent Res, 2013, 92: 860-867

[66] Bonewald LF. The amazing osteocyte. J Bone Miner Res, 2011, 26: 229-238

[67] Hernrisksen K, Neutzsky-Wulff AV, Bonewald LF, Kardsal MA. Local communication on and within the bone controls bone remodeling. Bone, 2009, 44: 1026-1033

[68] Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone, 2008, 42: 606-615

[69] Teti A. Mechanisms of osteoclast-dependent bone formation. Bonekey Rep, 2013, 2: 449

[70] Eastell R, Hannon RA. Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc, 2008, 67: 157-162

[71] Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int, 2009, 20: 843-851

[72] McCloskey EV, Vasikaran S, Cooper C FRAX® Position Development Conference Members Official positions for FRAX^® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX^®. J Clin Densitom, 2011, 14: 220-222

[73] Chavassieux PM, Delmas PD. Bone remodeling: biochemical markers or bone biopsy? J Bone Miner Res, 2006, 21: 178-179

[74] Schafer AL, Vittinghoff E, Ramachandran R, Mahmoudi N, Bauer DC. Laboratory reproducibility of biochemical markers of bone turnover in clinical practice. Osteoporos Int, 2010, 21: 439-445

[75] Vasikaran S, Eastell R, Bruyère O et al Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int, 2011, 22: 391-420

[76] Bauer D, Leary E, Silverman S et al National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int, 2012, 23: 2425-2433

[77] Lemming DJ, Alexandersen P, Kardsal MA, Qvist P, Schaller S, Tankó LB. An update of biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol, 2006, 62: 781-792

[78] Coen G, Ballanti P, Bonnucci E et al Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictively of intact PTH. Nephron, 2002, 91: 103-111

[79] Malluche HH, Manier-Faugere MC. Pth 1–84, Pth fragmants and bone turnover. Am J Kidney Dis, 2003, 41: 1127

[80] Coen G, Ballanti P, Bonnucci E et al Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant, 1998, 13: 2294-2302

[81] Couttenye MM, D’Haese PC, van Hoof VO et al Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant, 1996, 11: 1065-1072

[82] Krege JH, Lane NE, Harris JM, Miller PD. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int, 2014, 25: 2159-2171

[83] Hofbauer LC, Brueck CC, Singh SK et al Osteoporosis in patients with diabetes mellitus. J Bone Miner Res, 2007, 22: 1317-1328

[84] Inzerillo AM, Epstein S. Osteoporosis and diabetes mellitus. Rev Endocr Metab Disord, 2004, 5: 261-268

[85] Rosen CJ, Motyl KJ. No bones about it: insulin modulates skeletal remodeling. Cell, 2010, 142: 198-200

[86] Coen G. Adynamic bone disease: an update and overview. J Nephrol, 2005, 18: 117-122

[87] Farr JN, Drake MT, Amin S, Melton LJ3rd, McCready LK, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res, 2014, 29: 787-795

[88] Miller PD. Osteoporosis in patients with chronic kidney disease: diagnosis, evaluation and management. BoneKEy Rep, 2014, 3: 542

[89] Miller PD. Fragility fractures in chronic kidney disease: an opinion-based approach. Cleve Clin J Med, 2009, 76: 715-723

[90] Miller PD. Anti-resorptives in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab, 2008, 22: 849-868

[91] Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int, 2008, 19: 733-759

[92] Diab DL, Watts NB, Miller PD, Marcus R, Feldman D, Dempster D, Lucket M, Cauley J. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. Osteoporosis 2013, 2013 Waltham, MA Academic Press 1859-1872

[93] Lühe A, Künkele KP, Haiker M et al Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicol In Vitro, 2008, 22: 899-909

[94] Miller PD. The kidney and bisphosphonates. Bone, 2011, 49: 77-81

[95] Markowitz GS, Fine PL, Stack JI et al Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int, 2003, 64: 281-289

[96] Miller PD, Ragi-Eis S, Mautalan C, Ramimeriz F, Jonkamski I. Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease—the DIVINE study. Bone, 2011, 49: 1317-1322

[97] Rosen LS, Gordon D, Kaminski M et al Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 2003, 98: 1735-1744

[98] Saad F, Gleason DM, Murray R et al Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst, 2002, 94: 1458-1468

[99] Jamal SA, Bauer DC, Ensrud KE et al Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res, 2007, 22: 503-508

[100] Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res, 2005, 20: 2105-2115

[101] Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis—where do we go from here? N Engl J Med, 2012, 366: 2048-2051

[102] Shane E, Burr D, Abrahamsen B et al Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res, 2014, 29: 1-23

[103] Black DM, Schwartz AV, Ensrud KE et al FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA, 2006, 296: 2927-2938

[104] Khosla S, Bilezikian JP, Dempster DW et al Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab, 2012, 97: 2272-2282

[105] McClung M, Harris ST, Miller PD et al Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med, 2013, 126: 13-20

[106] Sambrook PN, Cameron ID, Chen JS et al Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int, 2011, 22: 2551-2556

[107] Thompson B, Towler DA. Arterial calcification and bone physiology: role of the bone–vascular axis. Nat Rev Endocrinol, 2012, 8: 529-543

[108] Peris P, Atkinson EJ, Gössl M et al Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women. Mayo Clin Proc, 2013, 88: 46-55

[109] Santos LL, Cavalcanti TB, Bandeira FA. Vascular effects of bisphosphonates—a systematic review. Clin Med Insights Endocrinol Diabetes, 2012, 5: 47-54

[110] Hruska KA, Saab G, Mattew S, Lund R. Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial, 2007, 20: 309-315

[111] Miller PD. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep, 2009, 7: 18-22

[112] Miller PD. A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis, 2011, 3: 271-282

[113] Reid IR, Miller PD, Brown JP et al on behalf of the Denosumab Phase 3 Bone Histology Study Group. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res, 2010, 25: 2256-2265

[114] Miller PD, Bolognese MA, Lewiecki EM et al for the AMG 162 Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone, 2008, 43: 222-229

[115] Cummings SR, San Martin J, McClung MR et al For the FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med, 2009, 361: 756-765

[116] McClung MR, Lewiecki EM, Geller ML et al Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int, 2013, 24: 227-235

[117] Kendler DL, Roux C, Benhamou CL et al Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res, 2010, 25: 72-81

[118] Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res, 2012, 27: 1471-1479

[119] Jamal SA, Ljunggren O, Stehman-Breen C et al Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res, 2011, 26: 1829-1835

[120] West SL, Lokb CE, Jamal SA. Osteoprotegerin and fractures in men and women with chronic kidney disease. J Bone Miner Metab, 2014, 32: 428-433

[121] Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotogerin in postmenopausal women. J Bone Miner Res, 2001, 16: 348-360

[122] Egbuna OI, Cheung AM, Siddhanti S, Wang A, Daizadeh N, Anthony M . Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification. J Bone Miner Res 2013; in press.

[123] Miller PD, Bilezikian JP, Deal C, Harris ST, Ci RP. Clinical use of teriparatide in the real world: initial insights. Endocr Pract, 2004, 10: 139-148

[124] Orwoll ES, Scheele WH, Paul S et al The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res, 2003, 18: 9-17

[125] Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab, 2000, 85: 3069-3076

[126] Saag KG, Shane E, Boonen S et al Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med, 2007, 357: 2028-2039

[127] Bilezikian JP, Matsumoto T, Bellido T et al Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res, 2009, 24: 373-385

[128] Neer RM, Arnaud CD, Zanchetta JR et al Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 2001, 344: 1434-1441

[129] Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int, 2007, 18: 59-68

[130] Dempster DW, Cosman F, Kurland ES et al Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res, 2001, 16: 1846-1853

[131] Chen P, Miller PD, Delmas PD, Misurski DA, Krege JK. Change in bone mineral density (BMD) and fracture risk reduction in teriparatide-treated women with osteoporosis. J Bone Miner Res, 2005, 20: S5

[132] Cannata-Andía JB, Rodriguez García M, Gómez Alonso C. Osteoporosis and adynamic bone in chronic kidney disease. J Nephrol, 2013, 26: 73-80

[133] Frazão JM, Martins P. Adynamic bone disease: clinical and therapeutic implications. Curr Opin Nephrol Hypertens, 2009, 18: 303-307

[134] Lindsay R, Scheele WH, Neer R et al Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med, 2004, 164: 2024-2030

[135] Miller Paul D., McCarthy Edward F.. Bisphosphonate-associated atypical sub-trochanteric femur fractures: Paired bone biopsy quantitative histomorphometry before and after teriparatide administration. Seminars in Arthritis and Rheumatism, 2015, 44 5 477-482

[136] Ng KW, Martin TJ. New therapeutics for osteoporosis. Curr Opin Pharmacol, 2014, 16: 58-63

[137] Pennypacker BL, Chen CM, Zheng H et al Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys. J Bone Miner Res, 2014, 29: 1847-1858

[138] Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol, 2013, 8: 819-823

[139] Bonewald LF. The amazing osteocyte. J Bone Miner Res, 2011, 26: 229-238

[140] McClung MR, Grauer A. Romosozumab in postmenopausal women with osteopenia. N Engl J Med, 2014, 370: 1664-1665

[141] Recker Robert R., Benson Charles T., Matsumoto Toshio, Bolognese Michael A., Robins Deborah A., Alam Jahangir, Chiang Alan Y, Hu Leijun, Krege John H, Sowa Hideaki, Mitlak Bruce H., Myers Stephen L.. A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density. Journal of Bone and Mineral Research, 2015, 30 2 216-224

[142] Polyzos Stergios A, Makras Polyzois, Efstathiadou Zoe, Anastasilakis Athanasios D. Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Expert Opinion on Investigational Drugs, 2014, 24 2 145-157